TO THE EDITOR

X-linked ichthyosis (XLI) is a rare dermatological condition characterized by abnormal desquamation and retention hyperkeratosis (Fernandes et al., 2010). It is caused by deficiency of the enzyme steroid sulfatase (STS), most frequently arising from genetic deletions on the X chromosome (Fernandes et al., 2010). XLI overwhelmingly affects males, although female carriers of XLI-associated variants may exhibit dry skin (Fernandes et al., 2010).

In males, XLI has been associated with an increased likelihood of cryptorchidism, innocuous corneal opacities, and neurodevelopmental/mood disorders and associated traits (Chatterjee et al., 2016; Fernandes et al., 2010; Rodrigo-Nicolás et al., 2018). Female carriers can exhibit delayed or prolonged labor during childbirth as a consequence of reduced placental STS activity and subsequent lower estrogen production and can exhibit a similar, although milder, constellation of neurodevelopmental/mood traits to affected males (Cavenagh et al., 2019). By using the large UK Biobank resource of approximately 0.5 million middle-aged individuals drawn from the UK general population and examining hospital-assigned International Classification of Diseases, Tenth Revision diagnoses, we recently identified atrial fibrillation/flutter as being diagnosed more frequently in males carrying deletions of 0.8–2.5 megabase (Mb) around STS than in male noncarriers (Brcic et al., 2020). To call copy number variants, anonymized genotype data were downloaded as raw CEL files from the UK Biobank website (https://www.ukbiobank.ac.uk/) and analyzed using Affymetrix Power Tools and PennCNV-Affy software (Wang et al., 2007), taking into account participants’ genotypic sex. Identifying comorbid medical conditions in XLI is key to ensuring optimal multidisciplinary care for affected individuals and for providing better genetic counseling.

Our original UK Biobank analysis screened for International Classification of Diseases, Tenth Revision diagnostic codes present in >2.5% of male deletion carriers and in >2,500 males in the overall sample; theoretically, this analysis might have missed conditions that are common in deletion carriers (i.e., present in at least 1 in 40 individuals) but are comparatively rare in the population as a whole. In this study, we report two additional diagnostic codes that are present in >2.5% of male XLI carriers but are generally rare (i.e., present in <2,500 of UK Biobank males). We have been prompted to present these findings now after recent discussions with males with XLI and female carriers in online patient support groups in which subchorionic hematomata during pregnancy and a high frequency of nosebleeds have been described by multiple deletion carriers.

“Haemorrhage and haematoma complicating a procedure, not elsewhere classified” was reported significantly more frequently in male deletion carriers than in male noncarriers (3.5% vs. 0.5%, P = 0.009) and more frequently in a mixed-sex sample of deletion carriers than in a mixed-sex sample of noncarriers (1.8% vs. 0.5%, P = 0.0071) (Table 1). Seven deletion carriers that were assigned this diagnostic code had a mean deletion size of 1.57 ± 0.10 Mb, with a 0.97 Mb consensus deletion interval spanning the HDHD1/PUDP, MIR4767, and STS genes (X:6,740,007–7,713,010, GRCh37 genome build). “Palmar fascial fibromatosis [Dupuytren]-Hand” was reported significantly more frequently in male deletion carriers than in male noncarriers (3.5% vs. 0.6%, P = 0.018) (Table 1). The four deletion carriers that were assigned this diagnostic code had a mean deletion size of 1.48 ± 0.20 Mb, with a 0.89 Mb consensus deletion interval spanning the VCX3A, HDHD1/PUDP, MIR4767, and STS genes (X:6,489,969–7,384,404, GRCh37 genome build). We did not identify any deletion carriers within our sample who had received a diagnosis of both “Haemorrhage and haematoma complicating a procedure, not elsewhere classified” and “Palmar fascial fibromatosis [Dupuytren]-Hand.” No individuals presenting with the aforementioned medical conditions had received a hospital International Classification of Diseases, Tenth Revision diagnosis of ichthyosis or had self-reported a previous diagnosis of blistering/desquamating skin disorder during an interview at the UK Biobank Assessment Centre; however, it should be noted that <5% of all male deletion carriers in UK Biobank self-reported such a condition, indicating substantial underdiagnosis or misdiagnosis of XLI in this cohort (Brcic et al., 2020).

To date, there is little published evidence for a biological link between STS deficiency and bleeding problems. However, such a link is plausible: in adult tissues, STS is most highly-expressed in the arterial vasculature (GTex Portal, 2021); the STS substrate, cholesterol sulfate, acts as an endogenous modulator of hemostasis (Sanchez et al., 2021); and circulating levels of a second STS substrate, dehydroepiandrosterone sulfate, have been associated with thrombus formation under certain conditions (Harrington et al., 2017; Roetker et al., 2018). Moreover, antepartum hemorrhage has been reported in a female carrier (Attenburrow et al., 1984). It is also possible that the apparent increased risk of hematoma/hemorrhage in deletion carriers is simply a correlate of these individuals being exposed to more surgical procedures.
procedures, or more invasive surgical procedures than noncarriers, for example, orchidopexy or emergency cesarean section.

Dupuytren contracture is a progressive fibrosing disorder arising from nodules and thickened cords in the palmar fascia that may lead to contractures of the fingers (Stewart and Nascimento, 2021). There is existing evidence that individuals with other forms of ichthyosis may exhibit contractures, thickening of the palmar fascia, and constricting bands of skin (Craiglow, 2013; Palmer and Louis, 1976), and acute inhibition of STS in mice has been associated with increased expression of the fibrosis-related genes Ccn2 (Ctgf) and Ccn3 (Nov) (Humby et al., 2016; Rebollodo et al., 2021).

The associations described in this study may be clinically relevant but are clearly provisional, with no accounting for multiple testing; hence, they will require replication and further investigation, for example, examining the extent to which they overlap with dermatological phenotypes. If confirmed, they will shed light on the biological basis of hemostasis and fibrotic conditions. We suggest that clinicians consider the possibility of the aforementioned (and related) conditions when evaluating males with XLI and female carriers.

Data availability statement

Datasets related to this article are available on application to UK Biobank (https://www.ukbiobank.ac.uk/).

Table 1. ICD-10 Descriptive Codes Identified in >2.5% of Male XLI Deletion Carriers and <2,500 Males Overall in UK Biobank Sample

| ICD-10 Descriptive Code                                                                 | UK Biobank Code | Group                      | Number Affected (%) | Fisher’s Exact Test Result |
|----------------------------------------------------------------------------------------|-----------------|----------------------------|---------------------|---------------------------|
| Palmar fascial fibromatosis [Dupuytren]-Hand                                           | 85340           | Male deletion carriers     | 3/86 (3.5)          | P = 0.018                 |
|                                                                                        |                 | Male noncarriers           | 1,214/190,577 (0.6) |                          |
|                                                                                        |                 | Female deletion carriers   | 1/312 (0.3)         | P = 0.364                 |
|                                                                                        |                 | Female noncarriers         | 329/227,862 (0.1)   |                          |
|                                                                                        |                 | Deletion carriers (male and female combined) | 4/398 (1.0) | P = 0.062                 |
|                                                                                        |                 | Noncarriers (male and female combined) | 1,543/418,439 (0.4) |                          |
| Haemorrhage and haematoma complicating a procedure, not elsewhere classified           | 142880          | Male deletion carriers     | 3/86 (3.5)          | P = 0.009                 |
|                                                                                        |                 | Male noncarriers           | 946/190,577 (0.5)   |                          |
|                                                                                        |                 | Female deletion carriers   | 4/312 (1.3)         | P = 0.109                 |
|                                                                                        |                 | Female noncarriers         | 1,315/227,862 (0.6) |                          |
|                                                                                        |                 | Deletion carriers (male and female combined) | 7/398 (1.8) | P = 0.007                 |
|                                                                                        |                 | Noncarriers (male and female combined) | 2,261/418,439 (0.5) |                          |

Abbreviations: ICD-10, International Classification of Diseases, Tenth Revision; XLI, X-linked ichthyosis.

REFERENCES

Attenburrow AA, Heslip M, Henderson MJ, Holton JB, Scott IV, Arthur LJ. Placental steroid sulphatase deficiency. Arch Dis Child 1984;59:1187–9.

Bricic L, Underwood JF, Kendall KM, Caseras X, Kirov G, Davies W. Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK Biobank. J Med Genet 2020;57:692–8.

Cavenagh A, Chatterjee S, Davies W. Behavioural and psychiatric phenotypes in female carriers of genetic mutations associated with X-linked ichthyosis. PLoS One 2019;14:e0212330.

Chatterjee S, Humby T, Davies W. Behavioural and psychiatric phenotypes in men and boys with X-linked ichthyosis: evidence from a worldwide online survey. PLoS One 2016;11:e0164417.

Craiglow BG. Ichthyosis in the newborn. Semin Perinatal 2013;37:26–31.

Fernandes NF, Janniger CK, Schwartz RA. X-linked ichthyosis: an oculocutaneous genodermatosis. J Am Acad Dermatol 2010;62:480–5.

GTExPortal. Gene Page. https://gtexportal.org/home/gene/STS; 2021. (accessed December 8, 2021).

Harrington LB, March BT, Wiggins KL, McKnight B, Heckbert SR, Woods NF, et al. Cross-sectional association of endogenous steroid hormone, sex hormone-binding globulin, and precursor steroid levels with hematotic factor levels in postmenopausal women. J Thromb Haemost 2017;15:80–90.

Humby T, Cross ES, Messer L, Guerrero S, Davies W. A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis. Psychoneuroendocrinology 2016;74:363–70.

Palmer AK, Louis DS. Flexion contractures of the hand associated with ichthyosis hystrix. Case report. J Bone Joint Surg Am 1976;58:143–4.

ORCIDs

Lucija Bricic: http://orcid.org/0000-0002-8115-3644
Georgina H. Wren: http://orcid.org/0000-0001-9179-136X
Jack F.G. Underwood: http://orcid.org/0000-0003-1731-6039
George Kirov: http://orcid.org/0000-0002-3427-3050
William Davies: http://orcid.org/0000-0002-7714-2440

*Corresponding author
e-mail: daviesw4@cardiff.ac.uk

AUTHOR CONTRIBUTIONS

Conceptualization: WD; Data Curation: LB, JFGU, GK, WD; Formal Analysis: LB, JFGU, GK, WD; Funding Acquisition: WD; Investigation: LB, JFGU, GK, WD; Methodology: LB, JFGU, GK, WD; Project Administration: WD; Supervision: WD; Writing - Original Draft Preparation: WD; Writing - Review and Editing: LB, GHW, JFGU, GK

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

This research has been conducted using the UK Biobank resource under Application Number 14421. The work was funded by a Cardiff University School of Psychology Research Internship (SPRINT) Programme grant to LB; by a Cardiff University School of Psychology PhD studentship to GHW; and by Medical Research Council Centre for Neuropsychiatric Genetics and Genomics (Centre Grant Number MR/L010305/1). JFGU is funded by a Wellcome Trust GW4-CAT Clinical Doctoral Fellowship (222849/Z/21/2).

Lucija Bricic¹, Georgina H. Wren¹, Jack F.G. Underwood²,³,⁴ George Kirov²,³ and William Davies¹,²,³,⁴,⁵

¹School of Psychology, Cardiff University, Cardiff, United Kingdom; ²MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom; ³Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom; and ⁴Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom
Rebolledo DL, Lipson KE, Brandan E. Driving fibrosis in neuromuscular diseases: role and regulation of connective tissue growth factor (CCN2/CTGF). Matrix Biol Plus 2021;11:100059.

Rodrigo-Nicolás B, Bueno-Martínez E, Martín-Santiago A, Cañueto J, Vicente A, Torrelo A, et al. Evidence of the high prevalence of neurological disorders in nonsyndromic X-linked recessive ichthyosis: a retrospective case series. Br J Dermatol 2018;179:933–9.

Roetker NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, Basu S, Cushman M, et al. Prospective study of endogenous hormones and incidence of venous thromboembolism: the atherosclerosis risk in communities study. Thromb Haemost 2018;118:1940–50.

Sanchez LD, Pontini L, Marinozzi M, Sanchez-Aranguren LC, Reis A, Dias IHK. Cholesterol and oxysterol sulfates: pathophysiological roles and analytical challenges. Br J Pharmacol 2021;178:3327–41.

Stewart BD, Nascimento AF. Palmar and plantar fibromatosis: a review. J Pathol Transl Med 2021;55:265–70.

Wang K, Li M, Hadley D, Liu R, Glessner J, Grant SFA, et al. Penn CNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007;17:1665–74.

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/